Clinical trials: Cancer, Bladder
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Cancer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either…
- Trial name
- NCT04485013
- Testing
- TTX-080, pembrolizumab, cetuximab
- Where
- 41 sites in United States
- Volunteers
- 240 people
- Sponsor
- Tizona Therapeutics, Inc
Urinary Bladder Neoplasms, Urologic Neoplasms
SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I
A multi-institutional, prospective, randomised, open-label, superiority, comparative, active-controlled, phase 3 study. The study will compare Synergo RF-induced hyperthermia-chemotherapy (SHTC) plus mitomycin C (MMC) to standard…
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms
- Trial name
- SHTC-EUROPE-1 (NCT02254915)
- Testing
- Synergo + MMC, Bacillus Calmette-Guérin
- Sponsor
- Medical Enterprises Europe B.V.
Urinary Bladder Neoplasms
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
The purpose of this study is to evaluate both the safety and tolerability of up to 4 dosing cycles of TAR-200 for 21 days per dosing cycle in the induction period.
- Trial name
- NCT03404791
- Testing
- TAR-200
- Where
- 12 sites in United States, Spain
- Volunteers
- 35 people
- Sponsor
- Janssen Research & Development, LLC
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Metastatic Renal Cell Carcinoma, Genitourinary Cancer (Bladder, Prostate or Testicular)
RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
The primary objective is to evaluate methods for AGS-003 production from surgical (stage I) and metastatic biopsy (stage II) Renal Cell Carcinoma (RCC) and a small subset of other GU cancers (expansion cohort) specimens using…
- Trial name
- NCT02026960
- Testing
- RNA extraction and amplification from biopsy specimens
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Duke University
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Home-Based Supportive Care Program for NMIBC Patients Receiving Intravesical Perfusion: Construction and Preliminary Application
This study focuses on patients with non-muscle-invasive bladder cancer who receive intravesical perfusion therapy. Outpatient perfusion treatment is usually short-term and procedure-oriented, so patients often lack continuous…
- Trial name
- NMIBC-HSC (NCT07781956)
- Testing
- Supportive care program, Implementing routine urology outpatient infusion nursing
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Bladder Cancer, Bladder Tumor
Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention
The main purpose of this study is to see if Prostaphane is effective and can help reduce the progression of bladder cancer. Researchers also want to find out if Prostaphane is safe and tolerable, and to evaluate how Prostaphane…
- Conditions
- Bladder Cancer, Bladder Tumor, Urothelial Carcinoma
- Trial name
- NCT03517995
- Testing
- Sulforaphane Administration, Standard of Care Surgery
- Where
- 2 sites in United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Bladder Cancer
Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma
Clinical trial to determine the performance characteristics (sensitivity and specificity) of the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology.
- Trial name
- NCT02647112
- Testing
- Bladder EpiCheck
- Where
- 6 sites in Germany, Israel and 2 more
- Volunteers
- 1,050 people
- Sponsor
- Nucleix Ltd.
Bladder Cancer
Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure
Patients with urothelial high risk non-muscle invasive bladder cancer patients will be treated with intravesical electromotive drug administration/mitomycin (EMDA/MMC) after bacillus Calmette-Guerin (BCG) failure.
- Trial name
- NCT04311580
- Testing
- intravesical electromotive administration of mitomycin
- Volunteers
- 52 people
- Sponsor
- University of Rome Tor Vergata
Invasive Bladder Cancer
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
Combined-modality treatment of localized muscle invasive bladder cancer including transurethral resection (TUR), radiotherapy and dual checkpoint inhibition immunotherapy could achieve pathological complete response in some…
- Trial name
- IMMUNOPRESERVE (NCT03702179)
- Testing
- Durvalumab, Tremelimumab, Radiotherapy
- Where
- 7 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Prostate Cancer, Urinary Incontinence
Augmented BLAdder NecK rEconstruction Trial for Improved Urinary Function After Radical Prostatectomy
The investigators are conducting a prospective, randomized trial to investigate whether patients randomized to receive an augmented bladder neck reconstruction (aBNR) at the time of robotic-assisted laparoscopic prostatectomy…
- Conditions
- Prostate Cancer, Urinary Incontinence, Surgery
- Trial name
- BLANKET (NCT04305379)
- Testing
- Augmented Bladder Neck Reconstruction, Standard Bladder Neck Reconstruction
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Johns Hopkins University
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE
Hemorrhage
Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology
Transurethral resection of the prostate (TURP) represents the gold standard in the operative management of benign prostatic hyperplasia (BPH) and the transurethral resection of bladder tumor (TURBT) is the first-line surgical…
- Trial name
- NCT02653261
- Testing
- Tranexamic Acid
- Where
- Tunisia
- Volunteers
- 131 people
- Sponsor
- University Tunis El Manar
Urinary Bladder Neoplasm
Role of Diffusion -Weighted MRI in Evaluation of Urinary Bladder Masses
Urinary bladder cancer is a common malignant tumor of the urinary tract in both men and women. Proper management of the urinary bladder cancer depends on the stage of the lesions.
- Trial name
- NCT05097105
- Testing
- MRI
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Bladder Cancer
Fast Track Protocol After Radical Cystectomy and Urinary Diversion: A Randomised Controlled Trial.
We will design a randomized controlled single center study in which we will compare 2 groups of patients, 1 with standard perioperative protocols and another one in which we will apply fast track protocols in patients after…
- Trial name
- NCT04939194
- Testing
- Fast Track Protocol
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Mansoura University
Bladder Cancer, Muscle-invasive Bladder Cancer
Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm
A two-arm multicenter randomised controlled trial, comparing progression free survival, time to definitive treatment and cost-effectiveness of the standard of care (TURBT) and mpMRI followed by same-day cystoscopic bladder biopsy…
- Trial name
- BladParadigm (NCT05779631)
- Testing
- mpMRI plus a same-day cystoscopic bladder biopsy, TURBT
- Where
- 19 sites in Netherlands
- Volunteers
- 360 people
- Sponsor
- Radboud University Medical Center
Urothelial Cancer, Bladder Cancer
Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
This study will evaluate the safety and efficacy of the combination of ABI-007, carboplatin and gemcitabine in the treatment of patients with advanced bladder cancer.
- Trial name
- NCT00995488
- Testing
- ABI-007 (Abraxane®)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
TURBT
Application of Pericapsular Nerve Group (PENG) Block
This study aims to determine the efficacy and safety of the Pericapsular Nerve Group (PENG) block in preventing obturator nerve reflex during transurethral resection of bladder tumors.
- Trial name
- NCT07078773
- Testing
- peng block, obturator nerve block
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.